Deng, Liang,Shuman, Stewart,Wolchok, Jedd,Merghoub, Taha,Wang, Weiyi,Dai, Peihong,Yang, Ning
申请号：
AU2017222687
公开号：
AU2017222687A1
申请日:
2017.02.25
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of a recombinant modified vaccinia Ankara (MVA) virus comprising an MVA harboring a human Fms-like tyrosine kinase 3 ligand (hFlt3L) (MVA-hFtl3L). The foregoing vaccinia Ankara (MVA) virus can be delivered to tumor cells of a subject afflicted with a malignant solid tumor, to treat the tumor. In a related aspect, the present disclosure concerns a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MV At.E3L) modified to express human Fms-like 5 tyrosine kinase 3 ligand (hFlt3L) isolated, suitable for use as an immunotherapeutic agent against a malignant solid tumor.
